For Biohaven Ltd. (BHVN), a global clinical-stage biopharmaceutical company focused on developing life-changing therapies for rare and common diseases, the second half of 2026 could be a defining chapter, with pivotal data readouts poised to shape the future of its diverse pipeline.
At the core of this innovation are its novel platforms, MoDE and TRAP, designed to target the root causes of autoimmune diseases. MoDE targets a class of proteins implicated in disease pathogenesis, while TRAP selectively removes disease-causing proteins while leaving the rest of the immune system intact.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.